TABLE 6.

Multivariate Cox regression analysis of MACE risk in patients with different CYP2C19 metabolizers.

Metabolic type	Variable	HR	95%CI	P值
EM type	Tica. (vs. Clop.)	1.05	0.36–3.02	0.931
	Age (for each additional year)	1.02	0.96–1.09	0.512
	Gender (M vs. F)	1.21	0.41–3.59	0.731
	Hypertension (yes vs. no)	1.35	0.45–4.08	0.592
	Diabetes (yes vs. no)	1.58	0.52–4.76	0.416
	Smoking (yes vs. no)	1.12	0.38–3.31	0.836
IM type	Tica. (vs. Clop.)	0.52	0.28–0.98	0.043
	Age (for each additional year)	1.03	0.99–1.07	0.105
	Gender (M vs. F)	1.18	0.64–2.18	0.601
	Hypertension (yes vs. no)	1.29	0.69–2.41	0.426
	Diabetes (yes vs. no)	1.45	0.78–2.70	0.241
	Smoking (yes vs. no)	1.09	0.59–2.01	0.782
PM type	Tica. (vs. Clop.)	0.32	0.11–0.89	0.029
	Age (for each additional year)	1.04	0.97–1.12	0.279
	Gender (M vs. F)	1.41	0.55–3.62	0.473
	Hypertension (yes vs. no)	1.62	0.63–4.17	0.318
	Diabetes (yes vs. no)	1.78	0.69–4.55	0.230
	Smoking (yes vs. no)	0.85	0.33–2.17	0.730

MACE, major adverse cardiovascular event;HR, hazard ratio; CI, confidence interval. Analysis was based on propensity score-matched cohort and adjusted for covariates listed in table.